Spine Fusion Instrumented With BMP-2 vs Uninstrumented With Infuse BMP-2 Alone

NCT ID: NCT00405600

Last Updated: 2013-02-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-11-30

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of spinal fusion is to relieve pain and/or increase stability in painful or unstable spine joints. A patient may or may not receive rods and screws with the use of bone graft materials to facilitate bone growth and a fusion thus preventing movement of the bones of the spine.

In this research study, bone graft substitute material called Bone Morphogenetic Protein-2 known as BMP-2 Infuse will be used. No hip bone will be used. The surgical procedure will consist of BMP-2 Infuse with or without the use of rods and screws.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study we will be using BMP-2 Infuse instead of the iliac crest bone graft for the spinal fusion. The BMP-2 Infuse has been researched in the only completed clinical trial for spinal fusions. It has demonstrated equivalence to the iliac crest bone graft with regard to both fusion rate and clinical outcome.

Currently, the acceptable standard of care for spinal fusion surgery requires instrumented or non-instrumented procedure with the use of bone graft materials, to facilitate bone growth, and a fusion, thus eliminating movement between the inciting vertebrae.

In this study, the surgical procedure will be BMP-2 Infuse with instrumentation or BMP-2 Infuse alone.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Degenerative Lumbar Disc Disease Spondylolisthesis Spinal Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Device

Device used in surgery with or without instrumentation

Group Type ACTIVE_COMPARATOR

Device used in surgery with or without instrumentation

Intervention Type PROCEDURE

Infuse Bone Graft BMP-2, Large Kit will be used in all surgeries. Spine surgeries will be either instrumented or uninstrumented.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Device used in surgery with or without instrumentation

Infuse Bone Graft BMP-2, Large Kit will be used in all surgeries. Spine surgeries will be either instrumented or uninstrumented.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient not currently participating in a drug or medical clinical trial.
* Patient signed informed consent.
* Patient is willing to be available for each examination scheduled over the study duration.
* Patient has clinical and radiologic history of degenerative disc disease or spondylolisthesis (no greater than grade 1 utilizing Meyerding's classification (Meyerding HW, 1932)); spinal stenosis for which conservative treatment has failed and lumbar spinal fusion is indicated.
* Eligible for non-instrumented or instrumented surgical procedure
* Has one or two levels (contiguous) involvement from L1-S1 requiring fusion
* Has preoperative Oswestry score greater than 30
* Has not responded to non-operative treatment for a period of 6 months (bed rest, physical therapy, medication, manipulations, spinal injections, other).
* Is at least 20 years of age inclusive at the day of surgery
* If female of childbearing potential, patient is non-pregnant, non-nursing, and agrees to use adequate contraception for one year following surgery.

Exclusion Criteria

* Patient has a systemic infection.
* Patient has had more than one previous non-fusion spinal surgery at the involved level.
* Patient requires fusion at more than 2 levels.
* Patient has pseudoarthroses from a previous fusion attempt.
* Patient has highly communicable diseases, inflammatory or autoimmune disease (e.g.osteomyelitis, crohn's, rheumatoid arthritis, systemic lupus, gout, HIV/AIDS, active tuberculosis, venereal disease, active hepatitis). A note to file written by the investigator will permit a patient into the study who experiences a mild case which will not affect the outcome of the study.
* Has been previously diagnosed with osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated
* Patient has a significant medical history that, in the Investigator's opinion would not make them a good study candidate.
* Patient requires interbody cage fusion or non-pedicle screw instrumentation.
* Pregnancy.
* Has presence of active malignancy (except basal cell carcinoma of the skin)
* Has a history of severe allergy (anaphylaxis)
* Is grossly obese, i.e. weight over 40% over ideal for their height and age.
* Has a fever (temperature over 101 F oral)
* Has an allergy to the BMP-2
* Has allergy to bovine products
* Has an allergy to collagen implants
* Is mentally incompetent(if questionable, obtain psychiatric consult)
* Is a prisoner, a transient or have been treated in an inpatient substance abuse program for alcohol and/or drug abuse within six months prior to proposed study enrollment.
* Has received drugs which may interfere with bone metabolism within two weeks prior to the planned surgery
* Has a diagnosis, which requires postoperative medication that interferes with fusion, such as steroids.
* Has history of endocrine or metabolic disorder known to affect osteogenesis (e.g. Paget's disease, renal osteodystrophy, Ehlers-Danios syndrome or osteogenesis imperfecta)
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nova Scotia Health Authority

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

David Alexander

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dr. David Alexander, M.D.

Role: PRINCIPAL_INVESTIGATOR

Capital Health District Authority, Centre for Clinical Research, Queen Elizabeth II, Health Sciences Centre, 1278 Tower Rd.,Halifax, Nova Scotia, B3H-9Z9, Canada

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Capital Health Health Authority, QEII Health Sciences Centre, Halifax Infirmary site,

Halifax, Nova Scotia, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CDHA016

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

rhBMP-2 in Cervical Arthrodesis
NCT02178605 COMPLETED
INDUCE: A Prospective 2-Year Spine Registry
NCT06971835 NOT_YET_RECRUITING
LUMBAR & SACROILIAC FUSION STUDY
NCT07204288 RECRUITING NA
Transforaminal Lumbar Interbody Fusion (TLIF)
NCT04073563 ACTIVE_NOT_RECRUITING NA
Titanium vs. PEEK Fusion Devices in 1 Level TLIF
NCT05691062 ENROLLING_BY_INVITATION PHASE4